GB-0895 golukibart Updated Nov 14
GB-0895 is the lead asset driving essentially all of GENB's valuation. Watch for updates on SOLAIRIA-1 and SOLAIRIA-2 enrollment completion and any disclosed Phase 3 topline timeline, as that will be the next major binary event. Also monitor Tezspire's (tezepelumab) commercial trajectory and label expansion, as it is the direct competitor and its performance sets market expectations for TSLP-targeting therapies. The Zealand Pharma partnership provides non-dilutive cash but is early-stage and adds no near-term revenue.
- GB-0895 is a potentially best-in-class anti-TSLP antibody designed for twice-yearly (every 6 months) subcutaneous dosing versus Tezspire's monthly injections, a significant convenience advantage that could drive adoption and market share in severe asthma.
- Phase 1 data presented at ERS 2025 showed a single dose produced sustained biomarker effects (reduced eosinophils, FeNO, IL-13, IL-5) for 6 months, supporting the extended dosing interval thesis.
- Analyst consensus is strongly positive: 11 analysts rate the stock a Buy or Strong Buy (only 1 Hold, no Sells), with a mean price target of $27 (approx 124% upside from the current ~$12).
- GB-0895 faces entrenched competition from Amgen/AstraZeneca's Tezspire (tezepelumab), the first approved anti-TSLP antibody that is already generating sales and expanding into additional indications like eosinophilic esophagitis (EoE) and COPD.
- Phase 3 trials involve ~1,600 patients across six global regions and are still recruiting (as of Q3 2026), suggesting a topline readout is likely years away; no near-term binary catalyst exists.
- The company is pre-revenue and burning cash (Q3 2026 net loss of $87.7M, revenue down 56% YoY). Despite $404.2M in cash, ongoing losses require capital discipline and the runway extends only to H1 2028.